Amid controversy and news of accelerated trials abroad, the latest report on Sputnik V suggests that the vaccine may meet its promised target and offers tolerable immunity after the first injection. Alexander Gintsburg, director of Moscow’s Gamaleya state research institute, which runs the trials, said that enough samples have been observed to conclude the safe operation of the vaccine. He also added that only one additional dose would be required to ‘extend’ the period of immunity. However, it is not clear how long the first immunity attack would last:
“For some, the protective level of antibodies occurs after the first vaccination and they need the second to extend that protection. They will probably be protected two weeks after the first vaccination, ”Gintsburg also said that the chances of reinfection after vaccination are likely to be“ low ”or“ weak ”.
“Yes there are [an infection between the first and second shots], it will occur in a weaker way. “
Russia is in the middle of a nationwide vaccination. The first batches of the vaccine are ready to be administered first to essential workers. Talks have also been held with India, with pharmaceutical giant Dr. Reddy’s, all set to bring the vaccine to India, produce ample doses for the public after it goes through the required phase III testing, authorizations and assents from DGCI. The administration could reportedly start from January next year.
.
